BioCentury | Apr 15, 2013
Company News

IDM SA board of directors update

Immuno-Designed Molecules S.A. , Paris, France Business: Gene/Cell therapy Appointed: Timothy Barberich, president and CEO of Sepracor Inc. (SEPR, Marlborough, Mass.) WIR Staff...
BioCentury | Jul 16, 2012
Company News

Orphan Synergy Europe-Pharma cancer news

...not disclosed. Loria was Epimmune's president and CEO from 2001 until the company merged with Immuno-Designed Molecules S.A....
BioCentury | Jul 14, 2012
Company News

OSE-Pharma debuts to resume development of EP2101

...$2.5-$6.2 million). Loria was Epimmune's president and CEO from 2001 until the company merged with Immuno-Designed Molecules S.A....
BioCentury | Apr 25, 2011
Company News

Biotech Synergy deal

...terms were not disclosed. EP-2101 was originally developed by Epimmune Inc. , which merged with Immuno-Designed Molecules S.A....
BioCentury | May 31, 2010
Finance

Performance Counts

...Swedish Orphan): SEK2.1B ($284.4M) Idea AG $16 Platform: drug delivery Diractin ketoprofen (IDEA-033) [IDEA] NA Immuno-Designed Molecules S.A....
BioCentury | Jun 4, 2007
Strategy

Rearview mirror

...In June 2004, Immuno-Designed Molecules S.A. pulled its proposed E99 million ($119 million) IPO on Euronext in Paris...
BioCentury | Jun 12, 2006
Company News

Neovacs management update

Neovacs S.A. , Paris, France Business: Infectious, Cancer Hired: Guy-Charles Fanneau de La Horie as CEO, formerly VP and a director at IDM S.A.; he replaces Alain Huriez, who is departing WIR Staff cancer Infectious...
BioCentury | Dec 12, 2005
Strategy

Westward Ho

...new biotech companies, it finds it difficult hanging onto those that are most ambitious, as Immuno-Designed Molecules S.A....
BioCentury | Aug 22, 2005
Company News

Epimmune, IDM SA deal

...basis. Post split, IDMI has 13.2 million shares outstanding. Epimmune Inc. (EPMN), San Diego, Calif. Immuno-Designed Molecules S.A....
BioCentury | Jul 25, 2005
Strategy

Choosing to survive

...is packing up and moving. The most widely noted example is French cancer immunotherapy company Immuno-Designed Molecules S.A....
Items per page:
1 - 10 of 54
BioCentury | Apr 15, 2013
Company News

IDM SA board of directors update

Immuno-Designed Molecules S.A. , Paris, France Business: Gene/Cell therapy Appointed: Timothy Barberich, president and CEO of Sepracor Inc. (SEPR, Marlborough, Mass.) WIR Staff...
BioCentury | Jul 16, 2012
Company News

Orphan Synergy Europe-Pharma cancer news

...not disclosed. Loria was Epimmune's president and CEO from 2001 until the company merged with Immuno-Designed Molecules S.A....
BioCentury | Jul 14, 2012
Company News

OSE-Pharma debuts to resume development of EP2101

...$2.5-$6.2 million). Loria was Epimmune's president and CEO from 2001 until the company merged with Immuno-Designed Molecules S.A....
BioCentury | Apr 25, 2011
Company News

Biotech Synergy deal

...terms were not disclosed. EP-2101 was originally developed by Epimmune Inc. , which merged with Immuno-Designed Molecules S.A....
BioCentury | May 31, 2010
Finance

Performance Counts

...Swedish Orphan): SEK2.1B ($284.4M) Idea AG $16 Platform: drug delivery Diractin ketoprofen (IDEA-033) [IDEA] NA Immuno-Designed Molecules S.A....
BioCentury | Jun 4, 2007
Strategy

Rearview mirror

...In June 2004, Immuno-Designed Molecules S.A. pulled its proposed E99 million ($119 million) IPO on Euronext in Paris...
BioCentury | Jun 12, 2006
Company News

Neovacs management update

Neovacs S.A. , Paris, France Business: Infectious, Cancer Hired: Guy-Charles Fanneau de La Horie as CEO, formerly VP and a director at IDM S.A.; he replaces Alain Huriez, who is departing WIR Staff cancer Infectious...
BioCentury | Dec 12, 2005
Strategy

Westward Ho

...new biotech companies, it finds it difficult hanging onto those that are most ambitious, as Immuno-Designed Molecules S.A....
BioCentury | Aug 22, 2005
Company News

Epimmune, IDM SA deal

...basis. Post split, IDMI has 13.2 million shares outstanding. Epimmune Inc. (EPMN), San Diego, Calif. Immuno-Designed Molecules S.A....
BioCentury | Jul 25, 2005
Strategy

Choosing to survive

...is packing up and moving. The most widely noted example is French cancer immunotherapy company Immuno-Designed Molecules S.A....
Items per page:
1 - 10 of 54